{"status": "OK", "response": {"docs": [{"type_of_material": "Op-Ed", "blog": [], "news_desk": "Editorial Desk", "lead_paragraph": "What are we going to do about Medicare? That should be the subject of an open national debate. But right now Congressional leaders are trying to settle the question by stealth, with legislation that purports to be doing something else. An aging population and rising medical costs will eventually require the nation to provide Medicare with more money or to cut benefits, or both. Meanwhile, there are demands for a new benefit: a gradual shift away from hospital treatment and toward the use of drugs has turned the program's failure to cover prescription drugs into a gaping hole.", "headline": {"main": "The Trojan Horse"}, "abstract": "Paul Krugman Op-Ed column calls Medicare bill under discussion in Congress a Trojan horse; says Republican politicians are using bill that would finally provide retirees with prescription drug coverage to smuggle in provisions that could undermine Medicare; notes one provisions under consideration would limit Medicare's use of general revenue, while another would force Medicare to compete with private insurers; says Democrats who understand exactly what is going on, such as Sen Ted Kennedy, are adamantly opposed to bill; says Republicans have retreated a bit, but bill is still a Trojan horse (M)", "print_page": "29", "word_count": 727, "_id": "4fd248df8eb7c8105d7e5fc8", "snippet": "What are we going to do about Medicare? That should be the subject of an open national debate. But right now Congressional leaders are trying to settle the question by stealth, with legislation that purports to be doing something else.    An aging...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/11/14/opinion/the-trojan-horse.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "KENNEDY, EDWARD M"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "FINANCES"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "LAW AND LEGISLATION"}, {"name": "subject", "value": "BUDGETS AND BUDGETING"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Paul", "rank": 1, "lastname": "KRUGMAN"}], "original": "By PAUL KRUGMAN"}, "document_type": "article", "pub_date": "2003-11-14T00:00:00Z", "section_name": "Health; Opinion"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "House Republicans floated a compromise on Tuesday that they said could delay direct competition between private health plans and traditional Medicare, the most contentious issue in a bill to help millions of elderly people buy prescription drugs. Conservative House Republicans insist on such competition, in the belief that it would save money in the long run. But the idea is anathema to many Democrats, who say they fear that price competition would undermine traditional Medicare and increase costs for older beneficiaries who remain in the original program.", "headline": {"main": "House G.O.P. Offers Compromise in Hope of Ending Stalemate on Medicare Bill"}, "abstract": "House Republicans float compromise they say could delay direct competition between private health plans and traditional Medicare, most contentious issue in prescription-drug legislation (M)", "print_page": "16", "word_count": 671, "_id": "4fd29b098eb7c8105d87ac68", "snippet": "House Republicans floated a compromise on Tuesday that they said could delay direct competition between private health plans and traditional Medicare, the most contentious issue in a bill to help millions of elderly people buy prescription drugs.   ...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/11/12/us/house-gop-offers-compromise-in-hope-of-ending-stalemate-on-medicare-bill.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "UNITED STATES"}, {"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "LAW AND LEGISLATION"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Robert", "lastname": "PEAR"}], "original": "By ROBERT PEAR"}, "document_type": "article", "pub_date": "2003-11-12T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Science Desk", "lead_paragraph": "It depends on what is meant by ''happy'' and ''smart.'' There are already drugs that brighten moods, like Prozac, and other antidepressants that control levels of a brain chemical called serotonin. While originally meant to treat depression, these drugs have been used for other psychological conditions like shyness and anxiety and even by otherwise healthy people to feel better about themselves.", "headline": {"main": "Can Drugs Make Us Happier? Smarter?"}, "abstract": "President's Council on Bioethics, addressing growth in antidepressant drug sales and research, reports that while some drugs make people feel happier they cannot create happy life; memory drugs, which are still being developed, likewise, will not make humans smarter, but show promise in improving person's ability to learn facts with less effort and practice; Dr Tom Tully, Cold Spring Harbor Laboratory researcher who has genetically engineered fruit flies with photographic memory, holds that memory enhancing drugs must be extremely safe for general use; drawing (M)", "print_page": "12", "word_count": 564, "_id": "4fd23a188eb7c8105d7ce2b7", "snippet": "It depends on what is meant by ''happy'' and ''smart.''    There are already drugs that brighten moods, like Prozac, and other antidepressants that control levels of a brain chemical called serotonin. While originally meant to treat depression, these...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/11/11/science/can-drugs-make-us-happier-smarter.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "PRESIDENT'S COUNCIL ON BIOETHICS"}, {"name": "organizations", "value": "COLD SPRING HARBOR LABORATORY"}, {"name": "subject", "value": "SALES"}, {"name": "subject", "value": "MEMORY"}, {"name": "subject", "value": "GENETICS AND HEREDITY"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "FLIES"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "ANTIDEPRESSANTS"}, {"name": "subject", "value": "FRUIT FLIES"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "DEPRESSION (MENTAL)"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2003-11-11T00:00:00Z", "section_name": "Science; Health"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "In the current debate over Medicare, no issue excites more passion than a proposal for it to compete directly with private health plans. Conservative House Republicans say they will not vote for a Medicare drug bill unless it fosters such competition, which they see as a way to slow the growth of Medicare spending. But many Democrats say they cannot vote for any bill that requires competition because it would undermine traditional Medicare and could raise costs for people who remain in that program.", "headline": {"main": "Issue of Competition Causes Widest Split Over Medicare"}, "abstract": "Demand by Conservative House Republicans that Medicare compete directly with private health plans is key issue threatening Medicare coverage for prescription drugs as Congressional negotiators try to reconcile House and Senate bills; proponents hold competition would slow growth of Medicare spending; opponents say it could undermine traditional Medicare and raise costs for people who remain in that program (M)", "print_page": "18", "word_count": 932, "_id": "4fd24b218eb7c8105d7ea0ae", "snippet": "In the current debate over Medicare, no issue excites more passion than a proposal for it to compete directly with private health plans.    Conservative House Republicans say they will not vote for a Medicare drug bill unless it fosters such...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/11/10/us/issue-of-competition-causes-widest-split-over-medicare.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "UNITED STATES"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "FINANCES"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "LAW AND LEGISLATION"}, {"name": "subject", "value": "BUDGETS AND BUDGETING"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Robert", "lastname": "PEAR"}], "original": "By ROBERT PEAR"}, "document_type": "article", "pub_date": "2003-11-10T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Week in Review Desk", "lead_paragraph": "IF the drug industry has a commercial Holy Grail, it might be an anti-aging pill, one that would let you live longer and prolong your youthful vigor. The market would be huge, of course. The problem is that to get it approved by the Food and Drug Administration, researchers would have to find a way to demonstrate that it works. To prove it was safe and effective, a company would have to give it to people and then wait to see if they lived longer than a control group that did not take the drug. The researchers might have to wait decades, by which time their patent protection rights -- 17 years, by current law -- would be long gone. The company would pay the costs of research and development, and the generic drug industry would reap the benefits.", "headline": {"main": "Ideas & Trends; The Drug Industry's Holy Grail"}, "abstract": "Work on anti-aging elixirs, potential Holy Grail of drug industry, described; photo; Elixir Pharmaceuticals founder Dr Leonard P Guarente explains its work on gene that is turned on with very low-calorie diets; testing might involve surrogate markers, indirect indictors that aging is being slowed (M)", "print_page": "12", "word_count": 861, "_id": "4fd23a1a8eb7c8105d7ce468", "snippet": "IF the drug industry has a commercial Holy Grail, it might be an anti-aging pill, one that would let you live longer and prolong your youthful vigor. The market would be huge, of course. The problem is that to get it approved by the Food and Drug...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/11/09/weekinreview/ideas-trends-the-drug-industry-s-holy-grail.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "GUARENTE, LEONARD P"}, {"name": "organizations", "value": "ELIXIR PHARMACEUTICALS"}, {"name": "subject", "value": "DIET AND NUTRITION"}, {"name": "subject", "value": "AGE, CHRONOLOGICAL"}, {"name": "subject", "value": "LONGEVITY"}, {"name": "subject", "value": "GENETICS AND HEREDITY"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "TESTS AND TESTING"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Gina", "lastname": "KOLATA"}], "original": "By GINA KOLATA"}, "document_type": "article", "pub_date": "2003-11-09T00:00:00Z", "section_name": "Health; Week in Review"}], "meta": {"hits": 5, "offset": 0, "time": 58}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}